O'Brien S - Search Results

1

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.

Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Seymour JF, et al. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.

2

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.

Ujjani C, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien S, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling A, Tu B, Sorensen T, Launchbury K, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA. Ujjani C, et al. Blood Adv. 2023 Sep 12;7(17):4728-4737. doi: 10.1182/bloodadvances.2022009164. Blood Adv. 2023. PMID: 36516082 Free PMC article.

3

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.

Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M, Jeyakumar D, Yaghmour G, Atallah EL, Gerds AT, O'Brien SM, Liesveld JL, Othus M, Litzow M, Stone RM, Sharon E, Erba HP. Advani AS, et al. Blood Adv. 2023 Apr 11;7(7):1279-1285. doi: 10.1182/bloodadvances.2022008216. Blood Adv. 2023. PMID: 36322825 Free PMC article.

4

Emerging data for venetoclax in chronic lymphocytic leukemia.

O'Brien SM. O'Brien SM. Clin Adv Hematol Oncol. 2022 Mar;20(3):178-183. Clin Adv Hematol Oncol. 2022. PMID: 36607348 No abstract available.

5

Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: leukemia and lymphoma.

O'Brien S. O'Brien S. Clin Adv Hematol Oncol. 2023 Jul;21(7):359-361. Clin Adv Hematol Oncol. 2023. PMID: 37477994 No abstract available.

6

Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia.

Lee BJ, Griffin SP, Doh J, Kongtim P, Chan A, O'Brien S, Jeyakumar D, Ciurea SO. Lee BJ, et al. Am J Hematol. 2023 May;98(5):E113-E115. doi: 10.1002/ajh.26880. Epub 2023 Feb 24. Am J Hematol. 2023. PMID: 36794446 Free article. No abstract available.

7

How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies.

Ma H, Wang S, O'Brien S, Kern M, Gupta P. Ma H, et al. Br J Haematol. 2023 Apr;201(2):215-221. doi: 10.1111/bjh.18661. Epub 2023 Jan 22. Br J Haematol. 2023. PMID: 36682358 Review.

8

Cancer: A targeted treatment with off-target risks.

Fruman DA, O'Brien S. Fruman DA, et al. Nature. 2017 Feb 23;542(7642):424-425. doi: 10.1038/nature21504. Epub 2017 Feb 15. Nature. 2017. PMID: 28199308 No abstract available.

9

[No title available]

[No authors listed] [No authors listed] PMID: 36164109

10

Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant.

Coombs CC, Easaw S, Grover NS, O'Brien SM. Coombs CC, et al. Cancers (Basel). 2023 Mar 18;15(6):1838. doi: 10.3390/cancers15061838. Cancers (Basel). 2023. PMID: 36980726 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,032 results

Search Page